Faron Pharma to expand its Clevegen trial to focus on Colorectal cancer
0 Views
administrator
07/07/23
Faron Pharmaceuticals Ltd's (LON:FARN) chief executive Markku Jalkanen tells Proactive London's Andrew Scott they're to target more patients with late-stage colorectal cancer as part of the ongoing phase I/II study of its Clevegen immunotherapy drug.
One of the patients currently enrolled in the trial has the most common form of colorectal cancer – called MSI-low – and has seen a “significant shrinkage” in lung metastasis.
The cohort expansion stage is planned for later this year once the optimal dose has been identified.
-
Category
Show more
Facebook Comments
No comments found